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Abstract
Connective tissue diseases of the skin are characterized by excessive collagen deposition in the skin and internal
organs. Fibroblasts play a pivotal role in the clinical presentation of these conditions. Nuclear receptor peroxisome-
proliferator activated receptors (PPARs) are therapeutic targets for dermal ﬁbrosis, but the contribution of the different
PPAR subtypes are poorly understood. Particularly, the role of ﬁbroblast PPARβ/δ in dermal ﬁbrosis has not been
elucidated. Thus, we generated a mouse strain with selective deletion of PPARβ/δ in the ﬁbroblast (FSPCre-Pparb/d−/−)
and interrogated its epidermal and dermal transcriptome proﬁles. We uncovered a downregulated gene, leucine-rich
alpha-2-glycoprotein-1 (Lrg1), of previously unknown function in skin development and architecture. Our ﬁndings
suggest that the regulation of Lrg1 by PPARβ/δ in ﬁbroblasts is an important signaling conduit integrating PPARβ/δ
and TGFβ1-signaling networks in skin health and disease. Thus, the FSPCre-Pparb/d−/− mouse model could serve as a
novel tool in the current gunnery of animal models to better understand dermal ﬁbrosis.
Introduction
Connective skin diseases are commonly characterized
by excessive deposition of collagen in the skin and
internal organs1, 2. The classical hallmark of collagen
overproduction is caused by myoﬁbroblasts that are
undergoing a dysregulated balance of signaling mediators,
including cytokines and growth factors, resulting in der-
mal ﬁbrosis that is observed in such diseases3. A proto-
typical and well-studied example of a connective skin
disease is scleroderma (SSc). To date, treatments for these
conditions exist only to provide symptomatic reliefs and
helps to prevent further complications4. The precise
etiology for the various clinical manifestations, however,
remains unclear. Many animal models have been devel-
oped to better understand the disease pathogenesis5, 6.
Although each animal model could not completely reca-
pitulate all aspects of connective tissue diseases, these
models collectively have advanced our understanding of
the different aspects of these conditions. Importantly, they
have underscored that connective tissue diseases, and the
underlying dermal ﬁbrosis and overproduction of col-
lagen, are multigenic and involves communications
among key cell types, such as keratinocytes, ﬁbroblasts,
and immune cells5–7.
Nuclear receptors (NRs) represent one of the largest
classes of transcription factors that are also known to be
druggable targets from the clinical perspective8–10. A
variety of skin diseases is currently treated with FDA-
approved drugs that target NRs, such as glucocorticoids
(cortisone) and vitamin D (calcitriol)11. There is a total of
48 NRs in humans, yet only a handful of them have well-
deﬁned roles in dermal ﬁbrosis and collagen
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overproduction, and thus are unexplored therapeutic
targets for these conditions12. The discovery of
peroxisome-proliferator activated receptors (PPARs) has
attracted attention due to their crucial role in lipid
homeostasis and tissue repair8, 11. There are three PPAR
subtypes: PPARα, β/δ, and γ. A recent study showed that
Fig. 1 (See legend on next page.)
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pan PPAR agonist IVA337 was effective in the prevention
and treatment of experimental skin ﬁbrosis13. The study
pointed to a role for PPAR in dermal ﬁbrosis, however,
the contribution of various PPAR subtypes remains
unclear. The skin of whole-body PPARγ heterozygous and
ﬁbroblast-speciﬁc PPARγ-deﬁcient mice did not exhibit
any signiﬁcant alterations in skin thickness or matrix
accumulation. Nonetheless, the deletion of PPARγ resul-
ted in enhanced susceptibility to bleomycin-induced skin
ﬁbrosis and speciﬁc agonists of PPARγ have been shown
to alleviate the extent of the development of cutaneous
sclerosis14, 15. As the most dominant PPAR subtype in the
skin, the role of epidermal PPARβ/δ in skin physiology is
well-documented16–19. Sclerodermic keratinocytes can
trigger an inﬂammatory response from the ﬁbroblasts via
secreted IL-1α20, 21. Interestingly, ﬁbroblast PPARβ/δ has
been shown to curb excessive epidermal proliferation
during wound healing via the production of secreted IL-1
receptor antagonist22. Several studies have suggested that
cellular redox state may play a signiﬁcant role in the
progression of scleroderma ﬁbrosis23, 24. Fibroblasts
obtained from the skin of patients with SSc showed
increase in reactive oxygen species production when
compared to normal ﬁbroblasts25. Incidentally, Wang et.
al. underscored a novel role of ﬁbroblast PPARβ/δ in the
modulation of oxidative stress in a diabetic wound
microenvironment26. These ﬁndings suggested a possible
role for ﬁbroblast PPARβ/δ in dermal ﬁbrosis. However,
whole-body PPARβ/δ knockout mice do not exhibit any
dermal ﬁbrotic phenotype8, 27–29, and this may be because
of a tissue-speciﬁc role for ﬁbroblast PPARβ/δ.
To understand the role of PPARβ/δ in ﬁbrotic skin
diseases, we generated a ﬁbroblast-selective PPARβ/δ
deleted mouse (FSPCre-Pparb/d−/−). FSPCre-Pparb/d−/−
mice exhibited profound morphological changes to the
skin architecture at an early age, pronounced wound
contraction and have altered gene expression proﬁle that
resembles ﬁbroproliferative diseases.
Results
PPARβ/δ-deﬁcient ﬁbroblasts enhance epidermal
hyperplasia and inﬂammation
We generated a mouse whose exons 4–5 of PPARβ/δ
gene were deleted in the ﬁbroblasts by crossing Pparb/dﬂ/ﬂ
with FSP1-Cre mice, herein called FSPCre-Pparb/d−/−.
The excision of Pparb/dﬂ/ﬂ was identiﬁed by the ampliﬁ-
cation of a 600-bp DNA fragment in dermal ﬁbroblasts
isolated from FSPCre-Pparb/d−/− and FSPCre-Pparb/
d+/- mice (Fig. 1a). Intact ﬂoxed Pparb/dﬂ/ﬂ appeared as a
2.2-kb band (Fig. 1a). Multiplex PCR of CD45+, CD31+,
and MHC+ revealed differential deletion of PPARβ/δ
allele in these isolated cells. No deleted PPARβ/δ allele
was observed in either CD31+ or MHC+ cells, whereas
PPARβ/δ was deleted in CD45+ cells (Fig. S1a). PPARβ/δ
mRNA and protein were not detected in ﬁbroblasts from
FSPCre-Pparb/d−/− mice (Fig. 1b, c). The relative
expression of PPARα and PPARγ in FSPCre-Pparb/d−/−
ﬁbroblasts was not altered when compared to that in
Pparb/dﬂ/ﬂ ﬁbroblast (Fig. 1b, c). This was similarly
observed in human dermal ﬁbroblasts whose endogenous
PPARβ/δ was suppressed by siRNA (Fig. S1b). The dele-
tion did not affect the number of pups per litter or gender
ratio (Fig. S1c). The body weight of male offspring was
signiﬁcantly lower than that of their wildtype counter-
parts, but this difference was not observed in female off-
spring (Fig. 1d, S1d). Thus, the FSPCre-Pparb/d−/−
mouse is viable and PPARβ/δ expression in ﬁbroblasts is
not critical for embryonic development.
To assess whether the FSPCre-Pparb/d−/− mouse
exhibited post-natal alterations, we performed histomor-
phometric analysis of the skin. The FSPCre-Pparb/d−/−
mice exhibited a thicker epidermis, dermis, and
(see ﬁgure on previous page)
Fig. 1 Pparb/d ablation in ﬁbroblasts enhances epidermal inﬂammation. a PCR analysis of mouse ﬁbroblast DNA. The non-deleted ﬂoxed allele
is represented by the 2.2-kb band. The Pparb/d-deleted allele is represented by the 600-bp band. n.c., negative control. b, c Relative PPARα, PPARβ/δ,
and PPARγ mRNA (b) and protein (c) levels in ﬁbroblasts of FSPCre-Pparb/dﬂ/ﬂ and Pparb/dﬂ/ﬂ mice. Representative immunoblots are shown. 18S rRNA
served as housekeeping gene. β-tubulin that served as housekeeping protein was from the same samples. Values are mean ± S.D. (n = 5). d Body
weight of male and female mutant mice over 6 weeks post birth. Values represent mean ± S.D. (n = 35 for male and n = 40 for female mice). e
Representative hematoxylin and eosin (H&E) stained skin sections from FSPCre-Pparb/dﬂ/ﬂ and Pparb/dﬂ/ﬂ mice at weeks 1, 4, and 8 of age. Scale bar =
50 μm. (n = 12). f Epidermis and dermis thickness in both genotypes at weeks 1, 4, and 8. Values represent mean ± S.D. (n = 31). g Relative protein
expression of epidermal markers for proliferation (PCNA) and differentiation (TGase1) in FSPCre-Pparb/dﬂ/ﬂ and Pparb/dﬂ/ﬂ mice at age week 4.
Representative immunoblots were shown. Coomassie stained of blots showed equal loading and transfer. β-tubulin that served as housekeeping
protein was from the same samples. Values represent mean ± S.D. (n = 5). h Barrier function test. Representative images of skins from FSPCre-Pparb/
dﬂ/ﬂ and Pparb/dﬂ/ﬂ mice topically treated with Lucifer yellow dye. Nuclei were stained with Hoechst dye (blue). Scale bar = 50 μm. i, j Graphs showing
the epidermal thickness (i) and the number of PCNA-positive keratinocytes (j) on dorsal skin treated with either vehicle (Veh) or 6.5 nmol of 12-O-
tetradecanoylphorbol-13-acetate (TPA) for 24 h. Values represent mean ± S.D. (n = 8). k Representative H&E stained section of TPA-treated skins from
FSPCre-Pparb/dﬂ/ﬂ and Pparb/dﬂ/ﬂ mice. Intra-epidermal microabscesses were observed in skins from FSPCre-Pparb/dﬂ/ﬂ mice. Scale bar = 200 μm.
Graph showing the relative protein expression of neutrophil marker Ly-6C/Ly-6G in Veh-treated and TPA-treated skin of FSPCre-Pparb/dﬂ/ﬂ compared
to Pparb/dﬂ/ﬂ mice. Representative immunoblots are shown. Coomassie stained of blots show equal loading and transfer. Values represent mean ± S.
D. (n = 5). *P < 0.05; **P < 0.01; ***P < 0.001; n.s. not signiﬁcant
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hypodermis (Fig. 1e, f, S1e). Immunohistochemical
staining and western blot analysis revealed an elevated
expression of PCNA (proliferation marker) as well as
transglutaminase type 1 (TGase1; differentiation marker),
suggesting an increase in the number of keratinocytes that
proceeded to differentiate (Fig. 1g, S1f–g). We did not
Fig. 2 Increased collagen deposition in dermis of FSPCre-Pparb/d−/− mice. a Representative Van Gieson’s stained sections of skins from FSPCre-
Pparb/d−/− and Pparb/dﬂ/ﬂ mice at weeks 1, 4, and 8. Scale bar = 50 μm. b Hydroxyproline content in FSPCre-Pparb/d−/− and Pparb/dﬂ/ﬂ mice at week
4. Hydroxyproline content was normalized to total protein concentration. Values represent mean ± S.D. (n = 5). c Mean number and cross-sectional
area of collagen ﬁbrils in the dermis of the FSPCre-Pparb/d−/− and Pparb/dﬂ/ﬂ mice at week 4. Values represent mean ± S.D. (n = 5). d Representative
images of immunoﬂuorescence staining for vimentin (green) and α-SMA (red) in dermis of both genotypes. Sections were counterstained with DAPI
for nuclei (blue). The dotted line represents the epidermis-dermis junction. Scale bar = 50 μm. e Relative protein expression of vimentin (vim) and α-
SMA in skin tissues from FSPCre- Pparb/d−/− and Pparb/dﬂ/ﬂ mice. Representative immunoblots for vimentin and α-SMA are shown. β-tubulin served
as housekeeping protein and was from the same samples. Values represent mean ± S.D. (n = 5). f Wound closure rate of full-thickness excisional
wounds on FSPCre-Pparb/d−/− and Pparb/dﬂ/ﬂ mice over a period of 18 days. Values are mean ± S.D. (Mann-Whitney U test; n = 7 per time point). g
Rate of wound contraction determined as the distance between the ﬁrst hair follicles on the wound edges. A 8-mm full-thickness excisional wound
was created on dorsal backs of mice. Wound biopsies were harvested at the indicated days post-wounding and stained with H&E. Values are mean ±
S.D. (Mann-Whitney U test; n = 10 per time point). *P < 0.05; **P < 0.01; ***P < 0.001; n.s. not signiﬁcant
Sng et al. Cell Discovery  (2018) 4:15 Page 4 of 16
detect differences in the penetration of Lucifer Yellow dye
into the epidermis of FSPCre-Pparb/d−/− and Pparb/dﬂ/ﬂ
mice (Fig. 1h), suggesting that the skin barrier function
was unaffected. Although, FSP1 has been reported to be a
key marker of a speciﬁc subset of macrophages in the liver
during ﬁbrosis and injury30, the FSPCre-Pparb/d−/− mice
neither exhibited hepatomegaly nor had increased col-
lagen deposition in the liver or gastrointestinal tract (Fig.
S1h–i).
Previous studies showed that global PPARβ/δ knockout
mice had an enhanced epidermal hyperplasia response
when topically treated with 12-O-Tetradecanoylphorbol-
13-acetate (TPA) compared to their cognate wild-type
littermates27, 28. We questioned the role of ﬁbroblast
PPARβ/δ in this acute TPA response, thus FSPCre-Pparb/
d−/− and Pparb/dﬂ/ﬂ mice were treated with TPA. We
observed an enhanced epidermal hyperplasia with more
PCNA-positive proliferating keratinocytes in FSPCre-
Pparb/d−/−mice compared to Pparb/dﬂ/ﬂmice in response
to topical TPA treatment (Fig. 1i, j, S1j–k). FSPCre-Pparb/
d−/− mice also exhibited intra-epidermal microabscesses
with greater inﬁltration of Ly-6C/Ly-6G-positive neu-
trophils (Fig. 1k, S1l). Thus, PPARβ/δ ablation in ﬁbro-
blasts led to an aggravated inﬂammatory response of the
adjacent epidermis to TPA.
FSPCre-Pparb/d−/− mice exhibit dermal thickening and
faster dermal wound healing
Dermal thickening was the most obvious phenotypic
difference between FSPCre-Pparb/d−/− and Pparb/dﬂ/ﬂ
mice. There was more collagen deposition in the FSPCre-
Pparb/d−/− dermis compared with Pparb/dﬂ/ﬂ as indi-
cated by Van Gieson’s stain and hydroxyproline mea-
surement (Fig. 2a, b). We also stained the tissues using
PicroSirus Red, which is intended for use in the histolo-
gical visualization of Type I and III collagen in red and the
cytoplasm in yellow. When viewed under polarized light
microscope, a red ﬂuorescence indicates the presence of
Type 1 collagen (Fig. S2a). Consistently, we observed a
thicker dermis and more collagen in the FSPCre-Pparb/d−/−
compared with Pparb/dﬂ/ﬂ mice (Fig. S2a). Focused ion
beam scanning electron microscopy of the dermis region
revealed a larger mean cross-sectional area but fewer
collagen ﬁbrils in FSPCre-Pparb/d−/− mice compared to
Pparb/dﬂ/ﬂ (Fig. 2c, S2b). We also detected more α-
smooth muscle actin (α-SMA)-positive myoﬁbroblasts, but
not vimentin-positive ﬁbroblasts in FSPCre-Pparb/d−/−
mice compared to Pparb/dﬂ/ﬂ mice (Fig. 2d, e). These
ﬁndings suggest that PPARβ/δ deﬁciency in ﬁbroblasts
promotes the activation of ﬁbroblasts to myoﬁbroblasts,
leading to increased dermal collagen deposition. To study
how this phenotype affects dermal wound healing, we
performed full-thickness excisional wounding assays.
FSPCre-Pparb/d−/− mice exhibited more rapid wound
closure than the Pparb/dﬂ/ﬂ mice (Fig. 2f, S2c), which was
associated with a signiﬁcantly higher rate of wound con-
traction (Fig. 2g, S2d). These observations suggest that the
higher number of myoﬁbroblasts and increased collagen
deposition with thicker collagen ﬁbers contributed to the
rapid wound contraction in FSPCre-Pparb/d−/− mice.
FSPCre-Pparb/d−/− mice exhibit a pro-ﬁbrotic gene
expression proﬁle
The above observations suggest that FSPCre-Pparb/d−/
− mice exhibited certain localized SSc-like hallmarks,
including excessive collagen deposition leading to thick-
ening of the dermis and greater number of myoﬁbroblasts.
Previous studies also concluded that localized SSc
involves autoimmune abnormalities with elevated levels of
anti-nucleosome antibodies31, 32. We detected higher
levels of anti-nucleosome antibodies in 69% of our
FSPCre-Pparb/d−/− mice, with a higher frequency in
female mice than male mice (Fig. S2e). To further
strengthen our ﬁndings, we performed comparative
microarray gene expression analysis of skin biopsies from
SSc patients, other mouse models of SSc and FSPCre-
Pparb/d−/− mice.
An intrinsic SSc gene set comprising 995 genes was
previously identiﬁed by Milano et al (GSE9285)33. We
examined the expression of these genes in the tight skin
(Tsk) 1 or 2 heterozygous mutant mouse model
(GSE71999), the bleomycin-induced ﬁbrosis mouse model
(GSE71999), the sclerodermatous graft versus host disease
(SGVHD) mouse model (GSE24410), and our FSPCre-
Pparb/d−/− mice (Fig. S3). Unguided hierarchical clus-
tering of samples revealed that the mouse models of SSc
mainly represented the ﬁbroproliferative subtypes of
human SSc. Both ﬁbroproliferative 1 and 2 subtypes of
human SSc share a common biological program of pro-
liferation33–35. FSPCre-Pparb/d−/− mice samples bran-
ched off from the same node as ﬁbroproliferative
2 subtype of human SSc samples, indicating that the gene
expression proﬁles of the two sample groups are highly
similar (Fig. S3).
A subset of 113 genes involved in cell:cell signaling and
interaction, connective tissue development and function,
and inﬂammation was downregulated in ﬁbroproliferative
human SSc compared with normal human skin (Fig. 3a).
On the one hand, only our FSPCre-Pparb/d−/− mice
recapitulated this molecular signature of the diseased
tissue, whereas these 113 genes were mostly upregulated
in the Tsk1/2, SGVHD and bleomycin-induced mouse
models of SSc. On the other hand, a subset of 110 genes
that was upregulated in human SSc samples was better
represented by Tsk1/2, SGVHD and bleomycin-induced
mouse models of SSc than FSPCre-Pparb/d−/− mice
(Fig. 3b). However, we noted that the gene ontologies
(GO) of deregulated genes in all mouse models of SSc,
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including our FSPCre-Pparb/d−/− mice, highlight con-
nective tissue abnormalities and inﬂammation as critical
processes in the development of SSc.
Because our FSPCre-Pparb/d−/− mice uniquely reca-
pitulated the cell:cell signaling aspect of ﬁbroproliferative
2 subtype of human SSc, we separated the epidermis and
the dermis of FSPCre-Pparb/d−/− mice skin to analyze
their compartment-speciﬁc gene expression by micro-
array. Genes that were differentially regulated by >1.5-
fold in the epidermis of FSPCre-Pparb/d−/− mice enri-
ched the GO of lipid metabolism, molecular transport,
small molecule biochemistry, cell death and survival, and
cellular movement, ranked according to their P-values (a
lower P-value indicates a stronger association to the
indicated GO) (Fig. 4a). A total of 80 unique gene tran-
scripts were responsible for the top three enriched GOs in
the epidermis. Among these 80 genes, 85% of them (68
genes: 37 upregulated, 31 downregulated) were lipid-
Fig. 3 Mouse models of SSc recapitulate the ﬁbroproliferative subset of human SSc. a Microarray datasets from FSPCre-Pparb/d−/− mice were
hierarchically clustered with microarray datasets from Tsk1/2 heterozygous mutant mice, bleomycin-induced ﬁbrosis mice, SGVHD mice, and human
SSc. Each mouse model or human disease cluster is represented by a unique color. Microarray datasets for other mouse models of SSc and human
SSc were downloaded from the NCBI GEO database. FSPCre-Pparb/d−/−mice (yellow box) uniquely recapitulated the expression pattern of 113 genes
in human ﬁbroproliferative SSc, i.e., 113 genes that were downregulated in human ﬁbroproliferative SSc were similarly downregulated in FSPCre-
Pparb/d−/−mice. Bar charts represent the gene ontologies (GO) associated with the 113 gene set, ranked by –log(P-value). Arrows represent GOs that
are highly relevant to SSc. b Tsk1/2 heterozygous mutant, bleomycin-induced ﬁbrosis, bleomycin-induced ﬁbrosis and SGVHD mice recapitulated the
expression pattern of 110 genes in human ﬁbroproliferative SSc, i.e., 110 genes that were upregulated in human ﬁbroproliferative SSc were similarly
upregulated in previous mouse models of scleroderma. Bar charts represent the gene ontologies (GO) associated with the 110-gene set, ranked by
–log(P-value). Arrows represent GOs that are highly relevant to SSc
Sng et al. Cell Discovery  (2018) 4:15 Page 6 of 16
related. 40 of these 68 genes (~60%) had overlapping
functions in inﬂammation, and 25 of these 40
inﬂammation-related genes (~63%) were involved in
TGFβ1 signaling (Fig. 4a, S4a). In the dermis, 58 genes
that were differentially regulated by >1.5-fold, enriched
the GOs of connective tissue development, tissue devel-
opment, cellular growth and proliferation, immune cell
trafﬁcking and inﬂammatory response. 49 of the 58 genes
(~85%) were migration/proliferation-related, 35 genes
(~60%) were connective tissue-related and 29 genes (50%)
were involved in TGFβ1 signaling (Fig. 4b, S4b).
The ﬁndings from microarray analysis of the two skin
compartments suggest that TGFβ1 signaling is a major
paracrine axis that is altered by the deletion of PPARβ/δ
in ﬁbroblasts. The microarray data is consistent with the
increased immune cell inﬁltration within the skin of
FSPCre-Pparb/d−/− mice compared with their wild-type
counterparts. This is also consistent with our current
observation of epidermal hyperproliferation in the skin of
FSPCre-Pparb/d−/− mice. These observations suggest
that the deletion of PPARβ/δ in ﬁbroblasts creates a
hotbed for facilitated immune cell entry, which is in part
responsible for thickening of the skin.
Fibroblast PPARβ/δ regulates Lrg1 to modulate
TGFβ1 signaling
The interrogation of our microarray datasets suggested
that dysregulated TGFβ1 signaling plays a central role in
the proﬁbrotic phenotype of FSPCre-Pparb/d−/− mice
(Fig. S4). Indeed, FSPCre-Pparb/d−/− mice exhibited an
enhanced activation of TGFβRII and SMAD3 via phos-
phorylation compared to Pparb/dﬂ/ﬂ mice (Fig. 5a). Of
interest is the diminished expression of LRG1 in the
dermis of FSPCre-Pparb/d−/− mice (Fig. 5b, S4b). LRG1
modulates TGFβ1 signaling in a tissue-speciﬁc manner
and has been implicated to play a role in vascularization36,
37. Thus, the role of LRG1 is aligned with the dysfunc-
tional microvascularization and dysregulated
TGFβ1 signaling observed in SSc patients. PPARβ/δ
agonist GW501516 (GW) increased LRG1 mRNA and
protein levels, which were attenuated either by PPARβ/δ
antagonist GSK0660 (GSK) or an inverse agonist com-
pound 10h (10h) in normal primary human ﬁbroblasts
(Fig. 5c, d). In silico analysis of the intragenic regulatory
region of mouse and human Lrg1 promoters revealed
putative PPAR response elements (PPREs) (Fig. S5).
Chromatin immunoprecipitation of primary mouse and
Fig. 4 Effect of TGFβ1 signaling on skin architecture in FSPCre-Pparb/d−/− mice. a Ingenuity pathway analysis (IPA) of genes differentially
expressed by >1.5-fold in FSPCre-Pparb/d−/− epidermis relative to Pparb/dﬂ/ﬂ epidermis. Top 5 gene ontologies (GO) (P < 0.0341) and their numbers of
constituent molecules were identiﬁed. Lower P-values indicate stronger associations with the indicated GO. Further stratiﬁcation of the 80 unique
molecules identiﬁed lipid-related, inﬂammation-related, and TGFβ-related sub-ontologies is shown. The bar chart represents the number of genes
upregulated (red) or downregulated (green) by >1.5-fold in FSPCre-Pparb/d−/−epidermis compared to Pparb/dﬂ/ﬂ epidermis. b IPA of genes
differentially expressed by >1.5-fold in FSPCre-Pparb/d−/−dermis relative to Pparb/dﬂ/ﬂ dermis. Top 5 GO (P < 0.0197) and their numbers of constituent
molecules were identiﬁed. Lower P-values indicate stronger associations with the indicated GO. Further stratiﬁcation of the 58 unique molecules
identiﬁed connective tissue-related, migration/proliferation-related, and TGFβ-related sub-ontologies. The bar chart represents the number of genes
upregulated (red) or downregulated (green) by >1.5-fold in FSPCre-Pparb/d−/−dermis compared to Pparb/dﬂ/ﬂ dermis
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Fig. 5 (See legend on next page.)
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human ﬁbroblasts showed that PPARβ/δ is recruited to
the PPRE of Lrg1 (Fig. 5e). These experiments identiﬁed
Lrg1 as a direct target of PPARβ/δ in ﬁbroblasts.
Microarray analyses revealed that the expression of
genes related to lipid mediators of inﬂammation was
upregulated in FSPCre-Pparb/d−/− epidermis (Fig. 4a).
One of the most upregulated genes was arachidonate 5-
lipoxygenase-activating protein (Alox5ap), which med-
iates inﬂammatory responses towards external stimuli38
(Fig. S4). The FSPCre-Pparb/d−/− mice expressed higher
levels of ALOX5AP mRNA and protein in the epidermis
than Pparb/dﬂ/ﬂ mice (Fig. 5f). Recombinant LRG1
decreased ALOX5AP expression in a dose-dependent
manner in primary human keratinocytes (Fig. 5g). These
results also suggest that the expression of ALOX5AP in
the epidermis was regulated, in part, by paracrine pro-
duction of LRG1 by the ﬁbroblasts. We conclude that the
upregulation of ALOX5AP in the epidermis of FSPCre-
Pparb/d−/− mice may contribute to the increased sus-
ceptibility of the epidermis to inﬂammatory insults.
The contractile and secretory α-SMA-positive myoﬁ-
broblasts contribute to tissue repair during wound heal-
ing, but organ function can be severely impaired when
contraction and collagen secretion become excessive,
such as in ﬁbrosis.3, 39 We studied the TGFβ1-mediated
α-SMA expression in LRG1-deﬁcient ﬁbroblasts (Fig. 5h,
i). LRG1 deﬁciency led to an increase in the mRNA levels
of TGFβRII and SMAD3, whereas treatment of LRG1-
deﬁcient ﬁbroblasts with recombinant LRG1 reduced
TGFβRII and SMAD3 expression (Fig. 5j). The increased
expression of α-SMA observed in LRG1-deﬁcient ﬁbro-
blasts was indicative of enhanced ﬁbroblast activation
(Fig. 5k), consistent with the higher number of α-SMA-
positive ﬁbroblasts in FSPCre-Pparb/d−/− mice. The
exposure to increasing doses of recombinant LRG1 pro-
tein decreased the expression of α-SMA in a dose-
dependent manner (Fig. 5k). To examine if recombinant
LRG1 protein could rescue the ﬁbrotic phenotype of
PPARβ/δ-deﬁcient ﬁbroblasts, we treated control (siS-
crambled) and PPARβ/δ-knockdown (siPPARb/d) human
ﬁbroblasts with TGFβ1 in the presence or absence of
recombinant LRG1 protein (Fig. 5l). TGFβ1 treatment
resulted in higher expression of phosphorylated SMAD3
(p-SMAD3) and α-SMA in siPPARb/d ﬁbroblasts when
compared with siScrambled ﬁbroblasts (Fig. 5l). Impor-
tantly, this increase expression of p-SMAD3 and α-SMA
was attenuated in the presence of recombinant LRG1.
Conversely, we treated siScrambled-knockdown and
LRG1-knockdown (siLRG1) human ﬁbroblasts with
TGFβ1 in the presence or absence of PPARβ/δ agonist
GW501516 (GW) (Fig. 5m). Similar to observation in
Fig. 5k, reduced LRG1 resulted in higher p-SMAD3 and
α-SMA, i.e., greater ﬁbroblast activation in siLRG1
ﬁbroblasts when compared with control. The co-
treatment with GW did not signiﬁcantly attenuate the
increase (Fig. 5m). Thus, LRG1 acted downstream of
PPARβ/δ and was able to rescue the ﬁbrotic phenotype of
PPARβ/δ-deﬁcient ﬁbroblasts.
These observations suggest a role of ﬁbroblast PPARβ/δ
in the homotypic regulation of TGFβ1 signaling, via
increased LRG1 production, in ﬁbroblast activation and
collagen production, which contribute to the ﬁbrotic
phenotype of FSPCre-Pparb/d−/− mice. Taken together,
our results indicate that in ﬁbroblasts, PPARβ/δ tran-
scriptionally upregulates Lrg1 that in turn acts in an
(see ﬁgure on previous page)
Fig. 5 Fibroblast PPARβ/δ modulates TGFβ1 signaling via LRG1. a, b Relative expression levels of phosphorylated TGFβRII and SMAD3 (a) and
LRG1 proteins in dermis and epidermis (b) from FSPCre-Pparb/d−/−and Pparb/dﬂ/ﬂ mice. Representative immunoblots for phosphorylated, total
TGFβRII and SMAD3, as well as LRG1 were shown. β-tubulin served as housekeeping protein was from the same samples. Values are mean ± S.D. (n =
5). c, d Relative LRG1 mRNA (c) and protein (d) levels in human ﬁbroblasts treated with GW501516 (GW), a speciﬁc PPARβ/δ agonist, and in
combination with GSK0660 (GSK), a PPARβ/δ antagonist, and compound 10h (10h), a PPARβ/δ inverse agonist. TBP, TATA-Box binding protein,
served as housekeeping gene for qPCR. Representative immunoblots are shown. β-tubulin that served as housekeeping protein was from the same
samples. Values are mean ± S.D. (n = 5). e Chromatin immunoprecipitation (ChIP) using PPARβ/δ antibodies or pre-immune Ig (p.i.) in human and
mouse ﬁbroblasts that were stimulated with either vehicle (Veh) or GW. Enrichment of either a PPRE-containing fragment from the endogenous Lrg1
promoter or a control DNA fragment (2 kb upstream of the PPRE) was evaluated by PCR. Aliquots of the extract were also analyzed before
immunoprecipitation (input). f, g Relative ALOX5AP protein level in skins from FSPCre-Pparb/d−/−and Pparb/dﬂ/ﬂ mice (f) and in human keratinocytes
treated with either TGFβ1 or recombinant LRG1 proteins (g). Representative immunoblots for ALOX5AP were shown. β-tubulin served as
housekeeping protein was from the same samples. Values represent mean ± S.D. (n = 5). h, i Relative LRG1 mRNA (h) and protein (i) levels in human
ﬁbroblasts transfected with either siRNA against LRG1 or scrambled siRNA control. 18 S rRNA served as housekeeping gene for qPCR. Representative
immunoblot for LRG1 is shown. β-tubulin that served as housekeeping protein was from the same samples. Values are mean ± S.D. (n = 3). j, k
Relative expression of TGFBR2, SMAD3 mRNAs (j) and α-SMA protein (k) in control, LRG1-knockdown human ﬁbroblasts, and LRG1-knockdown
human ﬁbroblasts treated with an increasing dose of recombinant LRG1 protein. 18S rRNA served as housekeeping gene for qPCR. Representative
immunoblot for α-SMA was shown. β-tubulin that served as housekeeping protein was from the same samples. Values are mean ± S.D. (n = 3). l, m
Relative protein levels of α-SMA, SMAD3, and phosphorylated SMAD3 (p-SMAD3) in PPARβ/δ- (siPparb/d) (l), LRG1- (siLRG1) knockdown ﬁbroblasts
(m) and control ﬁbroblasts transfected with scrambled siRNA (siScrambled). p-SMAD3 was normalized to total SMAD3 protein. β-tubulin that served
as housekeeping protein was from the same samples. Values are mean ± S.D. (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001; n.s. not signiﬁcant
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Fig. 6 PPARβ/δ and LRG1 reduce bleomycin-induced dermal ﬁbrosis. a Representative H&E stained sections of FSPCre-Pparb/d−/−and Pparb/dﬂ/ﬂ
mice skin treated with imiquimod cream 4% daily for 4 days compared to vehicle-treated (Veh) cognate mice. Scale bar = 50 μm. b Graph showing
the dermal thickness of Veh-treated and imiquimod-treated skins from indicated mice. Values represent mean ± S.D. (n = 5). c Representative H&E
stained sections of vehicle-treated and GW-treated skins from bleomycin-induced SSc. Scale bar = 150 µm. d Dermal thickness of vehicle-treated and
GW-treated skins from bleomycin-induced SSc. The dermal thickness of untreated FSPCre-Pparb/d−/−and Pparb/dﬂ/ﬂ mice skin was included for
comparison purpose. Values represent mean ± S.D. (n = 5). e Representative images of immunoﬂuorescence staining against cytokeratin 10 (CK10) in
bleomycin-injected mouse skin that was treated with either vehicle or the PPARβ/δ agonist, GW. Scale bar = 50 µm. f Hydroxyproline content in
vehicle-treated and GW-treated skins from bleomycin-induced sclerodermic mice. Hydroxyproline content was normalized to total protein
concentration. Values represent mean ± S.D. (n = 5). g Correlation plot of PPARβ/δ and LRG1 proteins in ﬁbroblasts from normal patients (n = 9) and
from scleroderma patients (n = 28). Representative immunoblots for PPARβ/δ and Lrg1 are in Supplementary Figure S5b. h, i Relative expression of α-
SMA protein in normal and sclerodermic ﬁbroblasts treated with either PPARβ/δ agonist (GW), antagonist (GSK), and inverse agonist (10h) (h) or
treated with increasing doses of recombinant LRG1 protein (i). Representative immunoblots for α-SMA are shown. β-tubulin that served as
housekeeping protein was from the same samples. Values are mean ± S.D. (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001; n.s. not signiﬁcant
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autocrine and paracrine manner to modulate tissue-
speciﬁc TGFβ1 effects.
Ligand-activated PPARβ/δ reduces the ﬁbrotic effect in SSc
Although the best treatment for localized SSc is
uncertain and current treatments often fail to help, ben-
eﬁts have been reported following topical 5% imiquimod
cream (Aldara®) treatment40–43. Imiquimod is an immune
response modiﬁer. It induces interferon and subsequently
inhibits TGFβ1 and was reported to attenuate SSc
symptoms in patients40. FSPCre-Pparb/d−/− mice topi-
cally treated with imiquimod exhibited a thinning of the
thickened dermis (Fig. 6a). The resultant dermal thickness
was no longer signiﬁcantly different from Pparb/dﬂ/ﬂ
(Fig. 6b). To evaluate the potential of PPARβ/δ as a
therapeutic target for dermal ﬁbrosis, we examined the
effect of the PPARβ/δ agonist GW on the widely used
bleomycin-induced mouse model of dermal ﬁbrosis.
Dermal ﬁbrosis was induced in C3H/He wildtype mice
through daily subcutaneous injection of bleomycin for a
period of 28 days. We concurrently co-injected them with
either dimethyl sulfoxide (DMSO) (vehicle) or GW. His-
tological analysis revealed that the dermis of the mice co-
treated with GW were thinner than that of mice co-
treated with vehicle (Fig. 6c, d). The epidermis of mice co-
treated with GW showed increased differentiation of the
epidermal layer by PPARβ/δ activation, as evidenced by an
increased CK10 staining (Fig. 6e). Hydroxyproline assay
also showed a lower level of collagen in the dermis of
GW-treated mice (Fig. 6f).
To further underscore the clinical relevance of PPARβ/
δ, we examined the effect of GW on human dermal
ﬁbroblasts that were explanted from 28 SSc patients.
Scleroderma ﬁbroblasts expressed lower levels of PPARβ/
δ mRNA and protein than normal ﬁbroblasts (Fig. 6g, h).
The protein level of LRG1 was lower in SSc ﬁbroblasts
than in normal ﬁbroblasts isolated from healthy volun-
teers (Fig. 6h). GW-activated PPARβ/δ reduced the
expression of α-SMA in SSc ﬁbroblasts, while the co-
treatment with either GSK or compound 10h (PPARβ/δ
inverse agonist) increased the expression of α-SMA
(Fig. 6i). Recombinant LRG1 similarly reduced the
expression of α-SMA in SSc ﬁbroblasts (Fig. 6j), indicating
that PPARβ/δ exerted its effect through LRG1, a direct
downstream target of PPARβ/δ. This observation sug-
gested that the activation of PPARβ/δ could reduce
ﬁbrosis, underscoring its therapeutic potential.
Discussion
Connective skin diseases are characterized by dermal
ﬁbrosis and excessive collagen deposition in the skin and
internal organs. Fibroblasts are the main producers of
collagen in the extracellular matrix, and thus the pivotal
cell type involved in the clinical presentation of
connective skin diseases, including SSc. Yet, the tran-
scriptional networks within the ﬁbroblasts that contribute
to dermal ﬁbrosis are not well-studied. We showed here
that ﬁbroblast PPARβ/δ is not critical for embryonic
development in mice. However, the epidermis of FSPCre-
Pparb/d−/− mice had an aggravated response to TPA,
suggesting that PPARβ/δ ablation in the ﬁbroblasts ren-
dered the mutant mice more susceptible to developing
inﬂammatory skin disorders. Notably, FSPCre-Pparb/d−/
− mice exhibited pronounced dermal thickening asso-
ciated with excessive collagen production, a greater
number of myoﬁbroblasts and Ly6-positive immune cells,
which somewhat represents a ﬁbrosing skin disorder
phenotype. These observations were also supported by
our comparative gene analyses, which showed that the
expression of the respective genes for collagen production
and immune cells activation were correspondingly altered.
The FSPCre-Pparb/d−/− mice exhibited dermal ﬁbrosis.
The skin of FSPCre-Pparb/d−/− mice was characterized
by increased collagen synthesis associated with increased
activation of ﬁbroblasts to myoﬁbroblasts. However,
FSPCre-Pparb/d−/− livers exhibited neither hepatome-
galy, which manifests with systemic SSc-associated pri-
mary biliary cirrhosis44, nor increased collagen deposition
in the intestinal wall, which could cause bowel hypomo-
bility45. These indicate that the role of PPARβ/δ in
ﬁbroblasts is likely to be tissue/organ-speciﬁc. We
detected dysregulated TGFβ1 signaling in the FSPCre-
Pparb/d−/− mice, which has been implicated in the
etiology of dermal ﬁbrosis46. Dermal ﬁbrotic symptoms
may be further aggravated by an enhanced epidermal
inﬂammatory response in these mutant mice. In clinical
settings, activated ﬁbroblasts give rise to an immune-
inﬂammatory environment with abnormal repair of
damaged vessels and ﬁbrosis47, 48 and ROS production49–
52. PPARβ/δ-deﬁcient ﬁbroblasts contribute to greater
microenvironment oxidative stress due to reduced
expression of antioxidant genes such as catalase and
glutathione peroxidase 126. Microarray analyses of
FSPCre-Pparb/d−/− skin revealed upregulation of
numerous genes that would culminate an increased ROS
production in the PPARβ/δ-ablated dermis, including
CCL2 and CCL5. Notably, CCL2 and CCL5 upregulation
was found to precede skin and lung ﬁbrosis in a mouse
model that recapitulates the pathology of SSc53. Finally,
we also identiﬁed gene networks in FSPCre-Pparb/d−/−
mice that closely resemble ﬁbroproliferative 2 subtype of
human SSc. Thus, the ﬁbroblast PPARβ/δ deﬁciency
causes dermal ﬁbrosis. Unlike FSPCre-Pparb/d−/− mice,
ﬁbroblast-speciﬁc PPARγ-deﬁcient skin did not exhibit
any manifestations of dermal ﬁbrosis or collagen over-
production, suggesting that ﬁbroblast PPARβ/δ and
PPARγ play different roles in skin physiology14. FSPCre-
Pparb/d−/− exhibited epidermal hyperplasia which is
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characteristic of psoriasis, another type of connective
tissue diseases. Several studies have also implicated a role
for PPARβ/δ in psoriasis54–58. However, the relative con-
tribution of epidermal and dermal PPARβ/δ in the etiol-
ogy and pathophysiology of psoriasis remains unclear.
This study is still ongoing in the lab, and is beyond the
scope of this work.
Our current study revealed that TGFβ1 signaling has an
overarching inﬂuence on skin architecture in FSPCre-
Pparb/d−/− mice. We identiﬁed Lrg1 as a direct down-
stream target of PPARβ/δ that contributes to the observed
phenotype. Thus far, LRG1 had been reported to augment
endothelial TGFβ1 signaling and promote angiogenesis36.
LRG1 is expressed in various human tissues, including the
breast, skin, and intestine, but little is known about its
role in these tissues. Our study shows that ﬁbroblast-
secreted LRG1 acts in a paracrine manner to inﬂuence the
epidermal TGFβ1 response to inﬂammatory challenges.
The underlying mechanism involved transcriptional
upregulation of LRG1 by ﬁbroblast PPARβ/δ, which
modulated homotypic and heterotypic TGFβ1 signaling.
Limitations of our study include that one genetic back-
ground of mouse and our deletion strategy consists of the
deletion of exons coding for the DNA-binding domain of
PPARβ/δ. It is also conceivable that other gene deletion
strategies may result in different phenotypic severity or
outcomes8. In addition to ﬁbroblasts, FSP1 driven gene
deletion may affect other cell types, although in vitro
experiments were performed to strengthen the conclu-
sion. Nevertheless, to the best of our knowledge, this is
the ﬁrst study to examine the role of ﬁbroblast PPARβ/δ
in skin, which reveals novel epithelial–mesenchymal
communication.
Current treatment of SSc is directed toward managing
complications and providing symptomatic relief.
Although several regimens have shown beneﬁt in case
series, few controlled trials have been performed and data
suggest wide variation in the approach to treatment59. For
example, topical 5% imiquimod cream has been reported
for the treatment of localized SSc40. We showed that
FSPCre-Pparb/d−/− mice were responsive to topical
treatment with imiquimod cream. The dermis of these
mice became thinner, resulting in a thickness similar to
that of their wildtype littermates. We also showed that
ligand-activated PPARβ/δ reduced dermal ﬁbrosis using
the bleomycin-induced mouse model of dermal ﬁbrosis.
In the 28 SSc patients analyzed, ﬁbroblasts consistently
had reduced level of PPARβ/δ and LRG1 compared to
healthy subjects. In addition, PPARβ/δ activation, or
LRG1 treatment, could reduce α-SMA levels in these
proﬁbrotic ﬁbroblasts. In conclusion, we identiﬁed an
important signaling conduit that integrates PPARβ/δ and
TGFβ1 signaling networks via LRG1 to be key players in
ﬁbrosis.
Materials and methods
Cell culture
Human keratinocytes (Lonza, USA) were routinely
cultured in keratinocyte-SFM culture media (Invitrogen,
USA). Fibroblasts were maintained in FibroGROTM
Medium (Millipore, USA). All cultures were maintained
in a humidiﬁed incubator at 37 oC with 5% CO2. Normal
human dermal and sclerodermic ﬁbroblasts were pro-
cured from Asterand Bioscience, UK and Proteogenex,
USA. Scleroderma patients were classiﬁed accordingly to
American College of Rheumatology criteria60. SSc
patients presented limited cutaneous SSc with skin
thickening was limited to hands and face. SSc patients
have Raynaud’s phenomenon for >5 years, minimal joint
pain and presented telangiectasias. The male:female ratio
was approximately 2:7. The balanced median age of the
normal (n= 9) and SSc (n= 28) donors were 42.8± 3.1
and 49.1 ± 2.5 years old, respectively. Due to the role of
PPARβ/δ in energy homeostasis, patients with diabetes,
obese patients (BMI> 30) or patients with hyperlipemia
were excluded. Skin ﬁbroblasts were isolated from skin
biopsy of the forearm using the explant method61 and
ﬂash frozen at the third passages for subsequent analysis.
Antibodies and chemicals
Primary antibodies used in this study: monoclonal anti-
α-SMA, PCNA, GAPDH, polyclonal anti-PPARβ/δ, β-
tubulin, TGase1, collagen type I and ALOX5AP (Santa
Cruz, USA); polyclonal anti-Ly6C/Ly-6G (BioLegend,
USA); polyclonal anti-vimentin and LRG1 (Abcam, USA).
IRDye® 680LT conjugated secondary antibodies were from
Li-Cor (Biosciences, USA); DyLight® conjugated second-
ary antibodies were from Vector Laboratories, USA.
GW501516 (PPARβ/δ agonist; GW), GSK0660 (PPARβ/δ
antagonist; GSK) and compound 10h (PPARβ/δ inverse
agonist; 10h) were synthesized in-house.
Generation of ﬁbroblast-selective PPARβ/δ-knockout mice
The PPARb/dﬂ/ﬂ mouse was provided by Prof Walter
Wahli (University of Lausanne, Switzerland). The PPARb/
dﬂ/ﬂ mouse carries alleles of the PPARβ/δ gene where the
exon 4, which encodes the DNA-binding domain, was
ﬂanked by loxP sites62, 63. The FSPCre transgenic mouse
expresses Cre recombinase under the control of the FSP1
promoter64. FSPCre mice were always maintained as
hemizygotes. FSPCre and PPARb/dﬂ/ﬂ mice were inde-
pendently backcrossed to C57BL/6J wild-type mice for at
least six generations. The FSPCre-Pparb/d+/- mouse was
generated in-house by crossing PPARb/dﬂ/ﬂ and FSPCre
mice. FSPCre-Pparb/d+/- progenies were bred with
Pparb/dﬂ/ﬂ mice to obtain FSPCre-Pparb/d−/− mice and
the wild-type control mice. To sustain this genotype, we
bred FSPCre-Pparb/d−/− progenies with Pparb/dﬂ/ﬂ mice.
Mice were housed in a speciﬁc-pathogen free facility with
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a 12 h/12 h light/dark cycle. Food and water were pro-
vided ad libitum.
Mice in the telogen phase of their hair cycle were
anaesthetized and depilated on their dorsal back before
being subjected to a biopsy punch (~8mm). The skin
biopsy was then treated with 3.8% ammonium thiocyanate
(Sigma, USA) in 1× PBS for 30min at 37 °C. Subse-
quently, the epidermis was mechanically separated from
the dermis with a pair of forceps. The dermis was then
curetted with a 30-gauge needle. The dermis was washed
with 1× PBS before being subjected to the genotyping
procedure, real-time qPCR assay and Western blot. Mice
genotyping were performed using the Mouse Genotyping
Kit HotStart as described by manufacturer (KAPA Bio-
systems, USA). Genotyping primers are provided in
Table S1.
Animal experiments were carried out in accordance to
the guidelines of the University Institutional Animal Care
and Use Committee (IACUC, ARF-SBS/NIE-A0216AZ,
A0321, and A0322), Singapore.
Real-time qPCR and Western blot
RNA extraction, reverse transcription, qPCR and wes-
tern blot were performed as previously described65. Total
RNA was extracted using TRIzol® as described by manu-
facturer (Invitrogen, USA). Reverse transcription was
performed using the iScriptTM Reverse Transcription
Supermix for RT-qPCR (Bio-Rad, USA) and qPCR done
using KAPA SYBR® FAST Universal qPCR Kit (KAPA
Biosystems, USA). Primer sequences are provided in
Table S1. Total protein was extracted using M-PER™
Mammalian Protein Extraction Reagent (ThermoFisher
Scientiﬁc). Infrared western blot was done as previously
described66. Protein bands were analyzed using the
Odyssey CLx scanner and Image Studio V2.1 (LI-COR
Biosciences, USA).
Histological, immunohistochemical, and
immunoﬂuorescence staining
Tissues were processed, sectioned and stained as pre-
viously described65. PicroSirius Red staining was per-
formed as recommended by the manufacturer (ab150681,
Abcam, Cambridge, United Kingdom). Colorimetric
images were captured using Axio Scan.Z1 with Plan
Apochromat 20×/0.8 objective (Carl Zeiss, Germany).
Fluorescence images were captured using the LSM 710
confocal microscope with the Zeiss EC Plan-NEOFLUAR
20×/0.5 NA objective. Analyses were performed with
ZEN 2012 Light Edition software (Carl Zeiss, Germany).
Lucifer yellow permeability assay
Lucifer yellow dye (1 mg/mL; Sigma-Aldrich, USA) was
topically applied on the epidermis for 1 h. Excess Lucifer
yellow was washed away with 1× PBS, and the skin
tissues were cryofrozen with OCT tissue freezing medium
(Leica, USA). Tissues were cryosectioned at 8 μm and
mounted with Hoechst 33,342 dye (Life Technologies,
USA). Images were taken using the LSM 710 confocal
microscope with the Zeiss EC Plan-NEOFLUAR 20×/0.5
NA objective. Analyses were performed with ZEN 2012
Light Edition software (Carl Zeiss, Germany).
Hydroxyproline assay
Hydroxyproline content in tissues was determined as
previously described67. Trans-4-hydroxy-L-proline
(0–300 µg/mL) was used to generate a standard graph.
Absorbance was measured at 550 nm using a SpectraMax
M2e Multi-Mode Microplate Reader and SoftMax Pro
Microplate Data Acquisition & Analysis Software (Mole-
cular Devices, USA). The value of unknown hydro-
xyproline was determined from the standard graph. The
weight of each respective wound biopsy was used for
normalization.
12-O-tetradecanoylphorbol 13-acetate (TPA)-induced skin
inﬂammation
Mice of ~4 weeks of age were shaven on their dorsal
skin and topically treated with 6.5 nmol of TPA (Sigma-
Aldrich, USA) in acetone for 24 h. The vehicle-treated and
TPA-treated skins were then harvested and processed
accordingly for histological studies and protein analysis.
Wounding experiment
Mice of ~8 weeks of age were shaved and full-thickness
excisional wounds were inﬂicted on the dorsal skin of
mice as previous described68. Wound surface areas and
contraction rates were measured over the indicated
duration.
Imiquimod topical application
Mice of ~8 weeks of age were shaved and subsequently
imiquimod cream 4% (Selleck Chemicals, USA) was
applied topically daily for a period of 4 days. Skin tissues
were then harvested and processed for histological
analysis.
Bleomycin-induced dermal ﬁbrosis
C3H/He mice of 4 weeks of age were subcutaneously
injected with 10 µg of bleomycin sulfate (Selleck Chemi-
cals, USA) together with either DMSO (n= 5) or 0.25 mg
of GW (n= 5) daily for a period 28 days69. Skin tissues
were then harvested and processed accordingly for his-
tological studies.
Gene expression microarray
cDNA synthesis was performed using the Applause
WT-Amp ST System (NuGEN Technologies, USA). The
resulting cDNA was puriﬁed with MinElute Reaction
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Cleanup Kit (Qiagen, USA), followed by fragmentation
and labeling using the Encore Biotin Module (NuGEN
Technologies, USA). The fragmented and labeled cDNA
were mixed with a hybridization master mix (Affymetrix,
USA) in accordance to the manufacturer’s protocol, and
90 μL of the resultant mixture were injected into the
GeneChip® Mouse Gene 1.0 ST Array gene chips (Affy-
metrix, USA). The scanned data was collected for analyses
using the Partek Genomics Suite v6.6 (Partek Inc., USA).
Differences in gene expression between FSPCre-Pparb/
d−/− and wild-type samples were identiﬁed using the
ANOVA function of the Partek Genomics Suite. Micro-
array datasets from FSPCre-Pparb/d−/− mice were sub-
sequently hierarchically clustered with microarray
datasets from tight skin (Tsk) 1 or 2 heterozygous mutant
mice (GSE71999), bleomycin-induced ﬁbrosis mice
(GSE71999), sclerodermatous graft versus host disease
(SGVHD) mice (GSE24410), and human samples of SSc
(PMC2481301, GSE9285), downloaded from NCBI Gene
Expression Omnibus (GEO) database. We focused our
analysis on an intrinsic SSc gene set comprising 995 genes
that was previously reported33 (GSE9285). Gene ontology
(GO) analysis of gene subsets was performed using the
Ingenuity Pathway Analysis software (Ingenuity Systems
Inc., USA). The microarray protocols and data have been
deposited in NCBI’s Gene Expression Omnibus (GEO)
database accession number GSE71419.
Chromatin immunoprecipitation (ChIP)
ChIP experiments were performed as previously
described65 except that anti-PPARβ/δ antibodies was used
(see above). ChIP primer sequences are listed in Table S1.
Transfection and luciferase assay
TGFβ1 responsive luciferase reporter assay in kerati-
nocytes was performed as previously described70. Luci-
ferase assay was performed using the Dual Luciferase®
Reporter Assay System and the Glomax 20/20 Lumin-
ometer (Promega, USA). The ON-TARGETplus
SMARTpool siRNA were used for knockdown studies
(Lrg1, Cat # L-056177-01; PPARβ/δ, Cat #L-042751-01;
Dharmacon). Cells were transfected using DharmaFect 1
as recommended by manufacturer. As control, the ON-
TARGETplus non-targeting control pool (D-001810-10;
Dharmacon) was used.
Anti-nucleosome antibody (ANA) detection
Mice of 4–6 weeks of age were studied for their ANA
levels. ANA levels in mice plasma samples were measured
by using the anti nucleosome IgG Antibody (AnuA, IgG)
BioAssayTM ELISA Kit (United States Biological, USA).
Readings were performed on the Inﬁnite® M200 Pro
machine (Tecan, Switzerland) with the MagellanTM
v7.0 software (Tecan, Switzerland).
Statistical analysis
Statistical analyses were performed using two-tailed
Mann-Whitney U test using SPSS software (IBM Cor-
poration, USA). A P-value of <0.05 was considered
signiﬁcant.
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